bioSyntagma Receives HSF Grant

Jan 9, 2017, 4:45 p.m.

Grant Provides Seed Funding for R&D into Tissue Heterogeneity

bioSyntagma, LLC announces the award of a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $213,904 to conduct basic research and development.  bioSyntagma develops life science tools for single and multi-cell analysis and this grant will help further develop the company’s unique microfluidic chip technology, the Light Stream FloCell™, which allows researchers to understand how disease-causing cells interact with each other. 

“bioSyntagma’s technology is indispensable for being able to answer fundamental medical questions relating to why cancers metastasize, which drugs are most effective for a patient at a given point in time, and what disease mechanisms are active in arthritis, diabetes, and dementia,” said David Richardson, CEO of bioSyntagma.

The LightStream FloCell™, or tissue chip, allows scientists, researchers, clinicians, and laboratory technologists to identify single cells, or areas of interests from routine biopsy tissues and move those cells using the tissue chip to a standard collection tube for further analysis.  This capability can help unlock the underlying mechanisms of diseases such as cancer, where differences in cells can cause resistance to even the latest cancer therapies, as well as diabetes and other autoimmune diseases like arthritis.

“The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts,” said Barry Johnson, director of the NSF’s Division of Industrial Innovation and Partnerships. “We hope that this seed funding will spark solutions to some of the most important challenges of our time across all areas of science and technology.”

bioSyntagma, a Center for Entrepreneurial Innovation client located on the GateWay Community College campus, is thrilled that the NSF recognizes the importance of its work, according to Richardson.

“This funding will allow us to further develop our technology, the application of which has profound implications in understanding the underlying causes across diverse disease states that have an enormous personal impact, and which are a heavy burden on our healthcare system and society.” 

About bioSyntagma:

bioSyntagma is a resident of the Center for Entrepreneurial Innovation located on the GateWay Community College campus and also a member of the Venture Devils program at Arizona State University.  bioSyntagma has an unmatched capability to extract single and multi-cells from a variety of sample types using a simple, and cost effective, microfluidic tissue chip, the LightStream FloCell™.  The bioSyntagma solution allows cells to be analyzed using advanced technology such as next generation sequencing, and link the resulting information to the spatial location of the sample within the original tissue.  This technology is indispensable for advancing scientific knowledge and the successful clinical treatment of cancer, diabetes, neurological disorders, and auto-immune diseases. The LightStream FloCell™ is a simple, easy to use device that will address workflow issues that prevent the widespread adoption of complex NGS technologies.  For more information on bioSyntagma, visit www.bioSyntagma.com